Over the past three years, the COVID-19 pandemic has dominated news headlines and spurred scientific innovation. Innovation in tools to combat malaria should take a page from the pandemic playbook: one benefit of the flood of COVID-19 research is that it demonstrated the enormous potential of monoclonal antibodies. These drugs are artificially synthesized laboratory-made copies of the proteins that a person’s immune system produces to destroy specific foreign invaders. 

Read the full op-ed on Project Syndicate's website.